Published in Lung Cancer on May 14, 2014
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | NCT01772004
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) | NCT01943461
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol (2016) 2.79
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One (2015) 1.26
Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med (2015) 1.23
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis (2015) 1.15
Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98
Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol (2016) 0.89
Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol (2015) 0.86
The management of brain metastases in non-small cell lung cancer. Front Oncol (2014) 0.85
Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition. Biomed Res Int (2015) 0.82
Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysis. Onco Targets Ther (2014) 0.80
Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res (2015) 0.79
Shedding light on the molecular determinants of response to anti-PD-1 therapy. Transl Lung Cancer Res (2015) 0.79
B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int J Clin Exp Pathol (2015) 0.77
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging (2016) 0.76
Apoptosis of Lewis Lung Carcinoma Cells Induced by Microwave via p53 and Proapoptotic Proteins In vivo. Chin Med J (Engl) (2017) 0.76
Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 Cells In Vitro and In Vivo. Biomed Res Int (2016) 0.75
Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer. Oncoimmunology (2014) 0.75
Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. Transl Oncol (2017) 0.75
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget (2015) 0.75
Nivolumab in Metastatic Non-Small Cell Lung Cancer. J Adv Pract Oncol (2016) 0.75
Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis. J Interferon Cytokine Res (2015) 0.75
Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment. P T (2014) 0.75
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. J Thorac Dis (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hallmarks of cancer: the next generation. Cell (2011) 140.01
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 6.58
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
New driver mutations in non-small-cell lung cancer. Lancet Oncol (2011) 6.03
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol (1987) 3.36
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol (2010) 3.06
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol (1998) 2.74
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol (2001) 2.71
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol (2013) 2.59
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori (2012) 2.55
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 2.12
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer (2014) 1.83
Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol (2000) 1.74
Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem (1997) 1.73
CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci U S A (1997) 1.69
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood (2013) 1.65
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol (2007) 1.53
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One (2012) 1.44
Role of GITR in activation response of T lymphocytes. Blood (2002) 1.36
CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol (2010) 1.29
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med (1999) 1.22
Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol (1978) 1.12
CD40/CD40L signaling and its implication in health and disease. Biofactors (2009) 1.11
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother (2012) 1.06
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med (2011) 1.06
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol (2009) 1.03
Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat (2001) 1.02
Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol (2012) 1.02
Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine (2004) 1.00
Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol (1995) 0.98
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol (2013) 0.97
Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One (2014) 0.96
Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother (2008) 0.96
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer (2011) 0.96
Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) (1992) 0.96
Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J (2013) 0.95
Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol (2010) 0.92
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol Lett (2013) 0.90
Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Cancer Res (2014) 0.88
[Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues]. Zhongguo Fei Ai Za Zhi (2010) 0.86
TIM3 expression by leukemic and non-leukemic myeloblasts. Cytometry B Clin Cytom (2013) 0.84
Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. Neoplasia (2013) 0.81
OX40 ligand: a potential costimulatory molecule in atopic asthma. J Asthma (2014) 0.78
CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother (2000) 0.78
CD40 expression in epidermal tumors. Anticancer Res (1997) 0.77
The A2A adenosine receptor is a dual coding gene: a novel mechanism of gene usage and signal transduction. J Biol Chem (2013) 0.76
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer (2016) 0.99
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. Lung Cancer (2017) 0.76